Aclaris Therapeutics ACRS Q3 2026: Beat, $50M Raise, and a Pipeline Catalyst

As seen on the 24/7 Wall St. homepage on November 5, 2026.

ACRS Aclaris Therapeutics
Q3 2026
EPS
-$0.12
est -$0.16 +25.8%
Revenue
$1M
est $1M +20.9%

A $50 million October raise just pushed Aclaris's cash runway through the first half of 2029, funding Phase 2b trials of ATI-052 and modzatinib. Top-line ADMIRATION results for bosakitug in atopic dermatitis land this quarter, making the next few weeks the real catalyst.

Continue ReadingShow less

Aclaris Therapeutics posted a Q3 2026 loss of $0.12 per share, beating the consensus estimate of roughly $0.16 by about 26%, while revenue of $1.48 million cleared expectations of $1.23 million by nearly 21%. The quarter's headline numbers were cleaner than they look at first glance: the reported EPS includes a $0.6 million gain from revaluation of contingent consideration, a one-time item that improved the bottom line relative to the year-ago period, which carried a $0.1 million charge on the same line.

Revenue fell 55% year over year, but the comparison is misleading in isolation. The prior-year quarter benefited from a Sun Pharma sales milestone that did not repeat, pulling licensing revenue from $2.81 million down to $1.18 million. Contract research contributed $300,000 of the total. Strip out that one-time prior-year item and the underlying business looks considerably more stable.

The more consequential news surrounds the pipeline. CEO Neal Walker highlighted strongly positive Phase 1b proof-of-concept results for ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in both severe atopic dermatitis and asthma. In the atopic dermatitis cohort, the drug produced a 45% placebo-adjusted mean EASI score change at week 8, a 78% placebo-adjusted EASI-50 response, and a 43% placebo-adjusted improvement in itch, with no conjunctivitis observed. The asthma data showed a 59% mean reduction in FeNO at day 15 alongside a 200 ml placebo-adjusted FEV1 improvement.

Sponsored

The company is now prioritizing ATI-052 for a Phase 2b trial in eosinophilic esophagitis, expected to start early next year, with a decision on a second Phase 2b indication in atopic dermatitis or asthma to follow shortly. Modzatinib, an oral ITK/JAK3 inhibitor, is set to begin a Phase 2b trial in lichen planus with first site activation in November 2026, an indication that currently has no approved therapies. An IND filing for ATI-9494, a dual ITK/TXK inhibitor, is also on track for the fourth quarter.

The most immediate catalyst on the calendar is top-line data from the Phase 2 ADMIRATION trial of bosakitug in 109 moderate-to-severe atopic dermatitis patients, expected before the end of Q4 2026. Investors got a clearer balance sheet to absorb that risk after Aclaris completed a $50 million equity raise in October 2026, issuing 7.8 million shares plus pre-funded warrants for 6.5 million additional shares. That raise extended the cash runway through the first half of 2029, giving the company time to absorb multiple readouts without an immediate financing overhang.

Mentioned: ACRS